OPINION ARTICLE

Public health research needs for molecular epidemiology and to emphasize homeostasis – could the omnipotent endopeptidase inhibitor α -2-macroglobulin be a meaningful biomarker? [version 1; peer review: 2 approved]

Frank Peter Schelp , Ratthaphol Kraiklang, Benja Muktabhant , Pornpimon Chupanit , Pattara Sanchaisuriya

Faculty of Public Health, Khon Kaen University, Khon Kaen, 40002, Thailand

V1 First published: 09 Jul 2019, 8:1025
<https://doi.org/10.12688/f1000research.19781.1>
 Latest published: 09 Jul 2019, 8:1025
<https://doi.org/10.12688/f1000research.19781.1>

Abstract

Public health authorities in low- and middle-income countries face dramatic challenges in handling rapidly increasing non-communicable diseases (NCDs), due to the epidemiological- and particularly nutritional transition. Among major reasons for the development of NCDs are smoking and alcohol, but overnutrition and obesity are also major threats to population health. Obesity is related to diabetes and cancer, but also has a genetic background. It is difficult to recommend a healthy nutrition. This is because of conflicting nutritional conceptions, and given the complexity of human metabolism understanding this topic can be difficult for the laymen. Public health measures advocating physical activity and refraining from high intake of energy, sugar and soft drinks need to be enhanced by supporting the 'intrinsic motivation' to preserve a good health. The mission of public health should be to increase awareness about the complexity of human metabolism, and the involvement of genetic and epigenetics in health and diseases. To maintain homeostasis, means to keep an optimal relationship between catabolism and synthesis, seems to be of particular interest. Preconditions for this is, that public health institutions within the administration- and academic sector follow up developments in life science and molecular biology and conduct population-based research making use of molecular epidemiology, especially those related to key metabolic steps and maintenance of 'homeostasis', in balancing catabolism and anabolism. A prospective biomarker for this situation might be α -2-macroglobulin.

Open Peer Review

Approval Status

	1	2
version 1		
09 Jul 2019	view	view
1. Florian J. Schweigert , University of Potsdam, Potsdam, Germany 2. Chaowanee Chupeerach , Mahidol University, Nakhon Pathom, Thailand		
Any reports and responses or comments on the article can be found at the end of the article.		

Keywords

Public health, non-communicable diseases, sustainable development goals, biomarkers, dietary restriction, homeostasis, metabolic syndrome, alpha-2-macroglobulin

Corresponding author: Frank Peter Schelp (f_schelp@kku.ac.th)

Author roles: Schelp FP: Conceptualization, Writing – Original Draft Preparation; Kraiklang R: Conceptualization; Muktabhant B: Conceptualization, Writing – Review & Editing; Chupanit P: Conceptualization; Sanchaisuriya P: Conceptualization

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Research Division of Khon Kaen University under the Excellence Centre for the Research Group on Prevention and Control of Diabetes Mellitus in the Northeast of Thailand.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Schelp FP *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Schelp FP, Kraiklang R, Muktabhant B *et al.* **Public health research needs for molecular epidemiology and to emphasize homeostasis – could the omnipotent endopeptidase inhibitor α -2-macroglobulin be a meaningful biomarker?** [version 1; peer review: 2 approved] F1000Research 2019, 8:1025 <https://doi.org/10.12688/f1000research.19781.1>

First published: 09 Jul 2019, 8:1025 <https://doi.org/10.12688/f1000research.19781.1>

Background

Non-communicable diseases (NCDs), such as cardiovascular diseases, diabetes, chronic obstructive pulmonary diseases and cancer, are the main focus of the Sustainable Development Goals (SDGs)¹. Target 3.4 of the SDGs intends to decrease premature death through NCDs by one third up to 2030. The four main risk factors mentioned are smoking, 'unhealthy' diets, physical inactivity and 'harmful' use of alcohol. Governments and public health authorities are encouraged to enforce so called 16 'best buy' strategies to reach the target. While it is well accepted that tobacco smoking and alcohol abuse are harmful for health and there is general agreement not to smoke and at least to refrain from too much or excessive alcohol consumption, campaigning against 'unhealthy' diets is more problematic. This is because of the complexity of how nutrition relates to health. The 'global obesity pandemic'² not only is caused by a surplus of energy in the diet, but it's link to diabetes³ and cancer^{4,5} and other diseases is driven by complex metabolic pathways⁶⁻⁹. Not only does overnutrition play a role in the development of cardiovascular diseases, cancer, diabetes and influences aging, but the risk for obesity is also related to genetic factors^{10,11}. Through epigenetic pathways under- and overnutrition of pregnant females might result in diabetes, cancer and cardiovascular diseases in their adult children¹²⁻¹⁵. Within the field of nutritional sciences matters are further complicated by recent developments of contradictory nutritional conceptions. There seems to be disagreement about what a healthy and appropriate diet should be and controversial opinions are justified by supportive investigations into molecular factors from both sides when either a 'low fat high carbohydrate-' or a 'low-carbohydrate, high fat diet' are promoted¹⁶.

The role of molecular epidemiology in public health actions against overnutrition

Governmental authorities and public health institution, overseeing the wellbeing of the population, cannot capitulate and stop promoting 'healthy' nutrition, in view of the constraints. So far major public health tools for working against NCDs, in regard to nutrition, are encouragement of physical activity, trying to influence behavior and practice through sophisticated methods of social sciences¹⁷, and to increase taxes on harmful products such as sugar and soft drinks with the intention to reduce consumption¹⁸. Benefit and drawbacks of these methods are not questioned here, but it has been argued by Slattery (2002) that 'while working at the population level of exploration, molecular epidemiology must incorporate knowledge from many disciplines to obtain an understanding of the organism, the system and the cell. Translating complex disease pathways into relevant public health messages should be the goal and the result of the art of epidemiology'¹⁹. Far too often interesting results within the field of genetics, insight into metabolic pathways and molecular components, such as enzymes and cytokines, escape the intention of those working in public health. This is plausible, as investigations using laboratory models, worms and rodents, are by no means research tools for public health. Studies exploring epigenetic effects, such as DNA methylation, as recently conducted in Estonia²⁰ are most probably not feasible for large scale epidemiological studies in

low- but also middle- and high middle income countries. However, low- and middle-income countries need to make use of advances in public health. In particular low-, but especially high middle-, income countries should have the means to follow up developments in molecular epidemiology in order to have a deeper understanding of the nature of NCDs, and should conduct as much population-based research as possible, including the use of promising biomarkers to give an insight into genetic and metabolic pathways.

In fact, besides anthropometry measurements, a number of clinical laboratory methods and biomarkers are already in common use and in future, epigenetic and molecular epidemiology could be additional suitable aspirants for population-based studies^{19,21,22}. However, multiple constraints in the use of biomarkers, as outlined for metabolic syndrome (MetS) should be considered.

Pros and cons of biomarkers – the examples of the components of the metabolic syndrome

In assessing the nutritional status using the body mass index (BMI) and other measurements as independent variables, MetS is frequently used as dependent variable since it incorporates a number of factors related directly or indirectly to NCDs. Variables associated with the syndrome include elevated blood glucose, dyslipidemia, abdominal obesity and high blood pressure. There are five different definitions of MetS, with different thresholds of its components. Because of this, and other controversial arguments, attempts have failed to agree on either version²³. As a compromise the use of the so called 'harmonized version' of MetS has been recommended²⁴. It is now considered that study participants categorized as exposed to MetS should be selected if they display three or more of the five criteria. However, this results in arbitrary groupings of individuals belonging to the 'MetS group', and individuals are integrated with one or two factors of MetS but less than three into the 'non-MetS' group. An example of using the 'harmonized version' MetS version in grouping study participants into the MetS- and the non-MetS group is given in Table 2 of a recent publication²⁵. To apply the 'harmonized version' weakens the validity of MetS as a dependent variable. The 'nature' of MetS as a 'syndrome' is also questioned. The term 'syndrome' should be used in case 'the whole is greater than the parts'²⁶, but this is doubtful²⁷ and before selecting MetS as independent variable it should be considered that a number of factors influence MetS such as age, sex and ethnicity.

Biomarkers representing key factor for the metabolism

As mentioned above, the use of MetS seems to be problematic and the recommendation of 'waist circumference' as a strong indicator of obesity and 'insulin resistance' as one of the metabolic key factors, could be a worthwhile alternatives for MetS²⁴. Waste circumference is a good measurement for overnutrition, because energy intake in excess is stored in the abdominal fat tissue. The adipokines of the fat tissue, by excreting inflammatory molecules, increase the risk to develop diabetes and cancer. Insulin resistance is 'the intersection' either for

the way to health or to metabolic disturbances. The absence of a general standard for waist circumference, however, is a disadvantage, and waist circumference needs to be standardized for different population groups²⁸, but with the homeostatic model assessment (HOMA) on hand, a method is available for estimating insulin resistance in epidemiological studies²⁹.

Trying to find and test biomarkers mirroring key metabolic steps for health and disease should be one major objective for molecular epidemiology. It is equally important to gain insight into the interaction of anabolism with catabolism. A candidate for the latter aspect is α -2-macroglobulin (α 2M). The importance of α 2M has been mentioned by Ohlsson 1972, stating that ' α 2M' may have a key role in the body's protection against autodigestion (cited by Schelp FP *et al.*³⁰), which implies that a complete deficiency will not be compatible with life. Within human plasma α 2M is the largest non-immunoglobulin, and an almost omnipotent inhibitor of endopeptidases with a unique way to deactivate proteinases³¹. The inhibitor is found in all mammals, and the biological significance for growth and differentiation can be judged by its presence during embryogenesis, pregnancy, childhood and in aging^{32,33}. A comprehensive overview about the molecular structure of α 2M, mechanism of action, function and pathophysiology is given in the review article from Rehman *et al.* (2013)³⁴.

α -2-Macroglobulin in health and disease

Besides the attention molecular biology has given to α 2M, in clinical settings the inhibitor was found to be related to the development of Alzheimer's³⁵. Low α 2M levels were observed in some patients with lung diseases³⁶, and in advanced prostate cancer³⁷, while in breast³⁸ and bladder cancer³⁹ elevated levels of α 2M were observed. It has been hypothesized that induced increase of endogenous proteinase inhibitors is protective against cancer⁴⁰. The assumption, among others, was based on the 'fat-related-cancer' hypothesis^{41,42}, and the low risk of vegetarians for cardiovascular diseases and cancer⁴³, as well as the finding that α 2M concentrations and other proteinase inhibitors were higher in Thai vegetarians compared with omnivores⁴⁴. It was argued that the balance between proteinases and their inhibitors are regulators of tumor growth. The role of proteinase inhibitors in connection with cancer protection considered a number of different inhibitors, and the specific role of α 2M remains vague since α 2M is incorporated in normal but not in tumor cells. In laboratory mice alpha macroglobulin is active through 'biomediators' but not through its inhibitory capacity⁴⁵. So far it was concluded that α 2M has a role in controlling normal but not malignant growth^{46,47}.

The role of α -2-macroglobulin in maintaining homeostasis in 'dietary restriction'

Obesity, as outlined above, is detrimental for health but 'dietary restriction', defined as 'reduced food intake by avoiding malnutrition', extends life span in animals and humans⁴⁸⁻⁵⁰. It has been demonstrated recently, by using a mouse model, that epigenetic modification in dietary restriction delayed aging and changed the gene expressions of the lipid profile⁵¹.

'Subclinical undernutrition' in preschool children could reflect 'dietary restriction without malnutrition'. The two forms of the condition are 'wasting', a deficit in weight for height and 'stunting', a deficit in height for age, adjusted to a standard⁵². Children categorized as wasting and stunting are apparently healthy without clinical signs of undernutrition. A number of investigation in Bangkok and villages in rural Thailand disclosed elevated α 2M levels and low 3-methylhistidine (3MH) urine excretion in healthy, age matched, village children in comparison to their Bangkok counterparts⁵³. 3MH is supposed to reflect muscle breakdown^{54,55}. A similar result was obtained when comparing normal nourished preschool children with those deficient in weight for height. α 2M serum concentration in the marginal nourished children increased over their well-nourished village counterparts⁵⁶. In an animal experiment with laboratory growing rats under a marginal diet, with altered protein and energy content, serum proteinase inhibitors increased and 3HM decreased⁵⁷. The results of the investigations support the hypothesis that in the situation of 'dietary restriction' proteinase inhibitors, including α 2M, decrease muscle catabolism, and in the case of the village children kept them healthy though 'an optimal relationship between catabolism and synthesis, thus resulting in stunting'⁵⁸. In case 'marginal nutritional intake', results in elevated α 2M serum concentrations, as expected, overweight and obese Thai adults in Bangkok, showed lower α 2M serum levels compared with normal individuals. The proteinase inhibitor selected as dependent variables in a multiple regression, resulted in a model including age, sex HDL cholesterol and BMI⁵⁹. A similar result was obtained studying hard working male construction laborers, in that a negative correlation were found for the variables age, weight, height, BMI, arm- and midarm circumference, triceps skinfold and HDL with α 2M as the dependent variable⁶⁰. α 2M of female construction workers did relate to any of the variables investigated. A dietary survey conducted with apparently health Thai farmers found a statistically significant negative correlation of α 2M with energy, protein, fat and carbohydrate intake⁶¹. All the results obtained from the variety of different studies seem to be in accordance with the assumption that α 2M supports homeostasis in situations of a 'challenged' nutritional status.

α -2-Macroglobulin in protein-energy-malnutrition

All the results obtained from the variety of different studies, as reviewed here, seem to be in accordance with the notion that α 2M supports homeostasis in situations of a 'challenged' nutritional status and suggest that proteinase inhibitors play a key role in maintaining the metabolism in balance. This also was assumed in observing patients suffering from clinical protein-energy malnutrition (PEM). The situation in PEM children is different from subclinical malnutrition. While increased proteinase inhibitors in wasting and stunting children somehow delay catabolism to maintain homeostasis, proteinase inhibitors increasing in seriously malnourished children, interrupt the mobilization of endogenous proteins which are needed to maintain homeostasis, for instance by providing essential amino acids. The increase of proteinase inhibitors aimed to counteract the proteases released in the course of infection, turn marasmus patients to develop

clinical symptoms of kwashiorkor³⁰. Comparing marasmus with kwashiorkor, the latter is the more serious condition.

Different levels of homeostasis

'Homeostasis', as a metabolic condition depends on age, sex, genetic and environmental factors, and is maintained on different levels. This has been pointed out by Pontzer (2015) using the example of energy expenditure and energy balance^{62,63}. This message from an evolutionary anthropologist is particularly important for public health in relation to physical activity. It is known that to lose weight by exercising has its limits. Increasing physical activity will lead to weight loss, however, excessive physical activity will not increase weight loss with increased energy expenditure; instead energy is acquired by using available resources used for basic functions of the organism under normal conditions. The consequence of this can be deadly in untrained individuals partaking in extreme physical activity e.g. a long run over 40 km. Winners of international marathon events are usually of African descent, whose 'homeostasis' allows them to cover the marathon distance in about two hours, while the rest of the field, using the rest of the day to finish the run. Homeostasis obviously can be achieved on different levels. The metabolism of the marathon winner allows them to economize energy expenditure much more efficiently as compared to other participants. In the regulation of the delicate balance of efficient energy expenditure, $\alpha 2M$ might play a key role and might help to better understand the mechanisms regulating total energy expenditure. Recently a genetic hint towards regulating endurance and fatigue of muscles has been described in a rodent model⁶⁴. Research in this direction might be a further step to allow a better understanding of important metabolic pathways related to energy expenditure and endurance.

Other important issues for public health are also waiting for further exploration, such as how to distinguish biological- from chronological age^{65,66} and whether 'dietary restriction' is 'beneficial' for health and if so, are there drawbacks to be observed

under certain circumstances and different ages. So for instance higher $\alpha 2M$ levels in connection with some biological substances called 'metallothioneins' are beneficial in young adults but might have a harmful role in aging³².

Conclusion

In view of the challenge of non-communicable diseases, the aim of those caring for the health of the population should support the 'intrinsic motivation' of individuals to remain healthy. This might not only be achieved by encouraging physical activity, and restrain from smoking, alcohol and overeating. Motivation to change 'bad' behavior and maintaining 'good behavior', requires understanding what 'bad' behavior is meant to be, and what 'homeostasis' means and how to maintain it. The nature of NCDs are not yet well understood. This hampers the formulation of clear recommendations for 'healthy' behavior and limits the trust of the general public in health messages. Public health authorities at least should try to follow up developments and assess the significance of what is increasingly becoming known about our metabolism. Last but not least, public health should contribute to translate findings in life science, by conducting research applying molecular epidemiology, in such a way that these findings are relevant for human population groups, and may even validate $\alpha 2M$ as a meaningful biomarker.

Data availability

Underlying data

No data are associated with this article.

Grant information

This work was supported by the Research Division of Khon Kaen University under the Excellence Centre for the Research Group on Prevention and Control of Diabetes Mellitus in the Northeast of Thailand.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Nugent R, Bertram MY, Jan S, *et al.*: **Investing in non-communicable disease prevention and management to advance the Sustainable Development Goals.** *Lancet*. 2018; **391**(10134): 2029–2035.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Swinburn BA, Sacks G, Hall KD, *et al.*: **The global obesity pandemic: shaped by global drivers and local environments.** *Lancet*. 2011; **378**(9793): 804–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kahn SE, Hull RL, Utzschneider KM: **Mechanisms linking obesity to insulin resistance and type 2 diabetes.** *Nature*. 2006; **444**(7121): 840–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Habib SL, Rojina M: **Diabetes and risk of cancer.** *ISRN Oncol*. 2013; **2013**: 583786.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Sun G, Kashyap SR: **Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations.** *J Nutr Metab*. 2011; **2011**: 708183.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Eckardt K, Taube A, Eckel J: **Obesity-associated insulin resistance in skeletal muscle: role of lipid accumulation and physical inactivity.** *Rev Endocr Metab Disord*. 2011; **12**(3): 163–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Maury E, Brichard SM: **Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome.** *Mol Cell Endocrinol*. 2010; **314**(1): 1–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
- O'Neill HM, Holloway GP, Steinberg GR: **AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: implications for obesity.** *Mol Cell Endocrinol*. 2013; **366**(2): 135–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Sun S, Ji Y, Kersten S, *et al.*: **Mechanisms of inflammatory responses in obese adipose tissue.** *Annu Rev Nutr*. 2012; **32**: 261–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Claussnitzer M, Dankel SN, Kim KH, *et al.*: **FTO Obesity Variant Circuitry and Adipocyte Browning in Humans.** *N Engl J Med*. 2015; **373**(10): 895–907.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Fawcett KA, Barroso I: **The genetics of obesity: FTO leads the way.** *Trends Genet*. 2010; **26**(6): 266–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bishop KS, Ferguson LR: **The interaction between epigenetics, nutrition and the development of cancer.** *Nutrients*. 2015; **7**(2): 922–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Drong AW, Lindgren CM, McCarthy MI: **The genetic and epigenetic basis of type**

- 2 diabetes and obesity.** *Clin Pharmacol Ther.* 2012; **92**(6): 707–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Ekamper P, van Poppel F, Stein AD, *et al.*: **Independent and additive association of prenatal famine exposure and intermediary life conditions with adult mortality between age 18-63 years.** *Soc Sci Med.* 2014; **119**: 232–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 15. Heijmans BT, Tobi EW, Stein AD, *et al.*: **Persistent epigenetic differences associated with prenatal exposure to famine in humans.** *Proc Natl Acad Sci U S A.* 2008; **105**(44): 17046–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 16. Ludwig DS, Willett WC, Volek JS, *et al.*: **Dietary fat: From foe to friend?** *Science.* 2018; **362**(6416): 764–770.
[PubMed Abstract](#) | [Publisher Full Text](#)
 17. Sørensen K, Van den Broucke S, Fullam J, *et al.*: **Health literacy and public health: a systematic review and integration of definitions and models.** *BMC Public Health.* 2012; **12**: 80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 18. Sassi F, Belloni A, Mirelman AJ, *et al.*: **Equity impacts of price policies to promote healthy behaviours.** *Lancet.* 2018; **391**(10134): 2059–2070.
[PubMed Abstract](#) | [Publisher Full Text](#)
 19. Slattery ML: **The science and art of molecular epidemiology.** *J Epidemiol Commun Health.* 2002; **56**(10): 728–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 20. Fischer K, Kettunen J, Würtz P, *et al.*: **Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons.** *PLoS Med.* 2014; **11**(2): e1001606.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 21. Fradin D, Bougnères P: **T2DM: Why Epigenetics?** *J Nutr Metab.* 2011; **2011**: 647514.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 22. Wild CP: **Complementing the genome with an “exposome”: the outstanding challenge of environmental exposure measurement in molecular epidemiology.** *Cancer Epidemiol Biomarkers Prev.* 2005; **14**(8): 1847–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
 23. O'Neill S, O'Driscoll L: **Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies.** *Obes Rev.* 2015; **16**(1): 1–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
 24. Alberti KG, Eckel RH, Grundy SM, *et al.*: **Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.** *Circulation.* 2009; **120**(16): 1640–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 25. Chupanit P, Muktabhant B, Schelp FP: **Dietary patterns and their association with the components of metabolic syndrome: A cross-sectional study of adults from northeast Thailand [version 1; peer review: 1 approved, 1 approved with reservations].** *F1000Res.* 2018; **7**: 905.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 26. Spellman CW, Chemitiganti RRV: **Metabolic syndrome: More questions than answers?** *J Am Osteopathic Association.* 2010; **110**(Supplement 3): eS18–eS22.
[Reference Source](#)
 27. Eddy DM, Schlessinger L, Heikes K: **The metabolic syndrome and cardiovascular risk: implications for clinical practice.** *Int J Obes (Lond).* 2008; **32** Suppl 2: S5–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Huxley R, Mendis S, Zheleznyakov E, *et al.*: **Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk—a review of the literature.** *Eur J Clin Nutr.* 2010; **64**(1): 16–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. Song Y, Manson JE, Tinker L, *et al.*: **Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the Women's Health Initiative Observational Study.** *Diabetes Care.* 2007; **30**(7): 1747–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 30. Schelp FP, Migasena P, Pongpaew P, *et al.*: **Are proteinase inhibitors a factor for the derangement of homeostasis in protein-energy malnutrition?** *Am J Clin Nutr.* 1978; **31**(3): 451–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. Sottrup-Jensen L: **Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation.** *J Biol Chem.* 1989; **264**(20): 11539–42.
[PubMed Abstract](#)
 32. Mocchegiani EG, Giacconi R, Muti E, *et al.*: **Zinc-binding proteins (metallothionein and α -2 macroglobulin) as potential biological markers of immunosenescence.** In: Straub REM, E., editor. *NeuroImmune Biology.* Amsterdam: Elsevier; 2004; **4**: 23–40.
[Publisher Full Text](#)
 33. Tayade C, Esadeg S, Fang Y, *et al.*: **Functions of alpha 2 macroglobulins in pregnancy.** *Mol Cell Endocrinol.* 2005; **245**(1–2): 60–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Rehman AA, Ahsan H, Khan FH: **α -2-Macroglobulin: a physiological guardian.** *J Cell Physiol.* 2013; **228**(8): 1665–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Varma VR, Varma S, An Y, *et al.*: **Alpha-2 macroglobulin in Alzheimer's disease: a marker of neuronal injury through the RCAN1 pathway.** *Mol Psychiatry.* 2017; **22**(1): 13–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. Krüger U: **[Chronic obstructive lung disease and alpha-2-macroglobulin deficiency in serum—case report].** *Pneumologie.* 1993; **47**(9): 531–4.
[PubMed Abstract](#)
 37. Ohtani H, Saito M, Koshiba K: **Alpha-2-macroglobulin deficiency in patients with advanced prostate cancer.** *Oncology.* 1985; **42**(6): 341–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Vasishta A, Baker PR, Preece PE, *et al.*: **Serum and tissue proteinase-like peptidase activities in women undergoing total mastectomy for breast cancer.** *Eur J Cancer Clin Oncol.* 1984; **20**(2): 203–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Lemańska-Perek A, Lis-Kuberka J, Lepczynski A, *et al.*: **Potential plasma biomarkers of bladder cancer identified by proteomic analysis: A pilot study.** *Adv Clin Exp Med.* 2019; **28**(3): 339–346.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. Schelp FP, Pongpaew P: **Protection against cancer through nutritionally-induced increase of endogenous proteinase inhibitors—a hypothesis.** *Int J Epidemiol.* 1988; **17**(2): 287–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Carroll KK: **Experimental evidence of dietary factors and hormone-dependent cancers.** *Cancer Res.* 1975; **35**(11 Pt. 2): 3374–83.
[PubMed Abstract](#)
 42. Wynder EL: **Nutrition and cancer.** *Fed Proc.* 1976; **35**(6): 1309–15.
[PubMed Abstract](#)
 43. Dwyer JT: **Health aspects of vegetarian diets.** *Am J Clin Nutr.* 1988; **48**(3 Suppl): 712–38.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Pongpaew P, Boonyakarnkula N, Schelp FP, *et al.*: **Serum concentrations of alpha-2-macroglobulin and other serum proteinase inhibitors in Thai vegetarians and omnivores.** *Nutr Res.* 1994; **14**(3): 337–345.
[Publisher Full Text](#)
 45. Koo PH: **Characterization of growth-inhibitory activities associated with an alpha-macroglobulin of mice.** *Cancer Res.* 1982; **42**(5): 1788–97.
[PubMed Abstract](#)
 46. Saksela O, Wahlstrom T, Lehtovirta P, *et al.*: **Presence of alpha 2-macroglobulin in normal but not in malignant human syncytiotrophoblasts.** *Cancer Res.* 1981; **41**(6): 2507–13.
[PubMed Abstract](#)
 47. Zardi L, Carnemolla B, Cagnasso D, *et al.*: **Alpha-2-macroglobulin in normal and malignant human cells.** *Eur J Cancer.* 1980; **16**(1): 35–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. Cava E, Fontana L: **Will calorie restriction work in humans?** *Aging (Albany NY).* 2013; **5**(7): 507–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 49. Fontana L, Partridge L: **Promoting health and longevity through diet: from model organisms to humans.** *Cell.* 2015; **161**(1): 106–18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 50. Weindrich R, Walford RL, Fligiel S, *et al.*: **The retardation of aging in mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake.** *J Nutr.* 1986; **116**(4): 641–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
 51. Hahn O, Grönke S, Stubbs TM, *et al.*: **Dietary restriction protects from age-associated DNA methylation and induces epigenetic reprogramming of lipid metabolism.** *Genome Biol.* 2017; **18**(1): 56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 52. Waterlow JC, Buzina R, Keller W, *et al.*: **The presentation and use of height and weight data for comparing the nutritional status of groups of children under the age of 10 years.** *Bull World Health Organ.* 1977; **55**(4): 489–98.
[PubMed Abstract](#) | [Free Full Text](#)
 53. Pongpaew PS, Schelp FP, Vudhivai N, *et al.*: **Alpha-2-macroglobulin, 3-methylhistidine and other biochemical parameters in preschool children of marginal nutritional status. Some evidence of an adaptation process in subclinical protein-energy malnutrition.** *Nutr Res.* 1988; **8**(11): 1213–1221.
[Publisher Full Text](#)
 54. Young VR, Alexis SD, Baliga BS, *et al.*: **Metabolism of administered 3-methylhistidine. Lack of muscle transfer ribonucleic acid charging and quantitative excretion as 3-methylhistidine and its N-acetyl derivative.** *J Biol Chem.* 1972; **247**(11): 3592–600.
[PubMed Abstract](#)
 55. Young VR, Munro HN: **Ntau-methylhistidine (3-methylhistidine) and muscle protein turnover: an overview.** *Fed Proc.* 1978; **37**(9): 2291–300.
[PubMed Abstract](#)
 56. Schelp FP, Pongpaew P, Sutjahjo SR, *et al.*: **Proteinase inhibitors and other biochemical criteria in infants and primary schoolchildren from urban and rural environments.** *Br J Nutr.* 1981; **45**(3): 451–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. Sarisnerand V, Schelp FP, Hiller HH, *et al.*: **Nutritionally-induced elevation of serum proteinase inhibitors and reduced 3-methylhistidine excretion in the rat.** *Int J Vitam Nutr Res.* 1990; **60**(3): 279–87.
[PubMed Abstract](#)

58. Pongpaew PS, Schelp FP: **Endogeneous increase of proteinase inhibitors as a possible mechanism of adaptation and subclinical undernutrition resulting in stunting.** *Nutr Res.* 1996; **16**(11–12): 1839–1845.
[Publisher Full Text](#)
59. Tungtrongchitr R, Pongpaew P, Vudhivai N, *et al.*: **Relationship between alpha-2-macroglobulin, anthropometric parameters and lipid profiles in Thai overweight and obese in Bangkok.** *Nutr Res.* 2003; **23**(9): 1143–1152.
[Publisher Full Text](#)
60. Schelp FP, Pongpaew P, Tungtrongchitr R, *et al.*: **Anthropometry, cholesterol, HDL and LDL in relation to alpha-2-macroglobulin in Thai construction site workers.** *Nutr Res.* 1996; **16**(7): 1153–1161.
[Publisher Full Text](#)
61. Pongpaew PS, Schelp FP, Supawan MTV, *et al.*: **Influence of dietary intake on alpha-2-macroglobulin and other biochemical parameters in healthy Thai males.** *Nutr Res.* 1991; **11**(6): 559–565.
[Publisher Full Text](#)
62. Pontzer H: **Constrained Total Energy Expenditure and the Evolutionary Biology of Energy Balance.** *Exerc Sport Sci Rev.* 2015; **43**(3): 110–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
63. Pontzer H, Raichlen DA, Wood BM, *et al.*: **Energy expenditure and activity among Hadza hunter-gatherers.** *Am J Hum Biol.* 2015; **27**(5): 628–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Okerblom J, Fletes W, Patel HH, *et al.*: **Human-like Cmah inactivation in mice increases running endurance and decreases muscle fatigability: implications for human evolution.** *Proc Biol Sci.* 2018; **285**(1886): pii: 20181656.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
65. Jylhävä J, Pedersen NL, Hägg S: **Biological Age Predictors.** *EBioMedicine.* 2017; **21**: 29–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
66. Underwood E: **The final countdown.** *Science.* 2015; **350**(6265): 1188–90.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 21 November 2019

<https://doi.org/10.5256/f1000research.21700.r53054>

© 2019 Chupeerach C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chaowanee Chupeerach

Institute of Nutrition, Mahidol University, Nakhon Pathom, Thailand

The manuscript is a good explanation of the need of molecular epidemiology in the public health area. This article reported the role of alpha 2 macroglobulin in the difference of metabolic state and it might be associated to homeostasis and health status. Therefore it could be a public health concern in the future.

However, the abstract should re-arranged to be more representative of the manuscript summary.

For the review body, to interpret and follow the role of alpha 2 macroglobulin, the reader might need more information about this protein in terms of molecular detail.

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Nutrigenomics, nutritional science

I confirm that I have read this submission and believe that I have an appropriate level of

expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 03 September 2019

<https://doi.org/10.5256/f1000research.21700.r51079>

© 2019 Schweigert F. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Florian J. Schweigert

Department of Physiology and Pathophysiology of Nutrition, University of Potsdam, Potsdam, Germany

The submitted manuscript is a very well written review on the possible use of a2-macroglobulin as a marker of metabolism. The manuscript describes the general need of valid and meaningful biomarkers in the context of NCDs in public health research, especially with regard to overnutrition and obesity. The manuscript covers the implication of overnutrition and obesity for public health and the need of biomarkers and suggests a2-macroglobulin as such. The main part of the manuscript describes in very much detail the current knowledge of a2M in metabolic function as an omnipotent inhibitor of endopeptidases. With regard to the topic of the manuscript the authors concentrate on the knowledge regarding a2M in energy homeostasis especially with regard to energy-protein malnutrition.

Comments:

- In general the manuscript itself is well written and balanced. However, the abstract is by no means reflecting the manuscript. It lacks condensed information on a2M and only addresses the general aspect of public health and the need of a biomarker.
- It is challenging for the reader to cite a citation with refers to another citation. It cannot be retrieved without greater efforts. See second section, page 4 of Ohlsson (1972), as cited by Schelp *et al.*

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: metabolism, micronutrient, biomarker

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research